Two of the investigational products in the European Medicines Agency’s priority medicines (PRIME) scheme for drugs for unmet medical need have now reached the stage where decisions are imminent on whether they will be accepted for review under the EU’s accelerated assessment procedure.
Jordi Llinares Garcia of the EMA revealed this development on May 19 at a meeting the agency hosted at its...